Update on Scheme and Supreme Court of NSW proceedings
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mayne Pharma Group Ltd. provides an update on its proposed acquisition by Cosette Pharmaceuticals and ongoing legal proceedings in the Supreme Court of New South Wales regarding the termination of the Scheme Implementation Deed. The court previously ruled in favor of Mayne Pharma, dismissing Cosette's claims, but Cosette has filed a notice of intention to appeal. Mayne Pharma is committed to implementing the acquisition scheme, pending certain approvals and a scheduled court hearing. The company will keep the market informed of any changes to the timetable related to the acquisition process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Mayne Pharma Group Ltd. on 6ix
Story so far
Earlier from Mayne Pharma
- MYX Scheme of Arrangement update on FIRB approval
- Outcome of litigation and update on Scheme
- MYX announces PBS listing of NEXTSTELLIS in Australia
- Mayne Pharma addresses recent media articles regarding FIRB
- 2025 Full Year Results Investor Presentation
Later from Mayne Pharma
- MYX - Panel Conducts Proceedings and Makes Interim Orders
- Update on FIRB approval and Scheme
- MYX Declaration of Unacceptable Circumstances and Orders
- Update on status of FIRB approval and second court hearing
- Pause in Trading
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma